AMD announces appointment of Dr Anthony Thomson to Advisory Panel and CEO to Life Science subsidiary, CoM3D
AMD is delighted to announce the appointment of Dr Anthony Thomson MSc MBA PhD FRSM to its Advisory Panel to advise on IP commercialisation. In addition, he will also take on the role of CEO of Life Science subsidiary company CoM3D which is working in conjunction with our partners at the University of Texas at Austin under the guidance of Dr Mohammed Maniruzzaman.
Anthony held numerous leadership roles in technology, automotive, health, capital markets and University sectors and has led the formation, growth and exit of several businesses including corporate ventures and University spin-outs, most recently managing a successful exit to US giant, Qualcomm.
AMD CEO John Lee says, “I have known Anthony several years and have sought his valuable guidance several times in the history of our company – I look forward to his growing involvement in our day to day business and especially in the application of his skills to the development of CoM3D”.
In addition to his work with AMD and COM3D, Anthony is also a Non-Exec director of a number of high growth SMEs across diverse sectors including Cyber Security, IT and Digital Transformation, Built Environment, Retail and Healthcare. His leadership roles include CBO of Elephants Child Advisory, Chief Strategy Officer at Isansys Lifecare and various senior roles at Qualcomm; University of Auckland; Euronext; ABN AMRO; BNP Paribas; LIFFE and Chesterton.
Anthony has an MSc and a PhD from the University of Otago (NZ) and is a Fellow of the Royal Society of Medicine. His strategic business skills are also recognised with an MBA from Cranfield School of Management where his thesis received the Deans Prize for its insight into commercialisation strategies for University technology. He has also completed the Proteus Leadership Programme at London Business School.